Skip to main content

Table 1 Baseline characteristics of patients in the standard therapy arm

From: Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

  Total ≥1 Grade 3/4 AEs ≥1 Related Grade 3/4 AEs
No of subjects 639 128 57
(% total)   (20.0%) (8.9%)
Gender (%)
 Male 447 79 (17.7%) 31 (6.9%)
 Female 192 49 (25.5%) 26 (13.5%)
Age
 <25yrs 187 37 (19.8%) 11 (5.9%)
 25–35yrs 184 29 (15.8%) 20 (10.9%)
 >35yrs 268 62 (23.1%) 26 (9.7%)
Baseline Weight
 <40kg 63 18 (28.6%) 8 (12.7%)
 40–45kg 103 29 (28.2%) 14 (13.6%)
 >45–55kg 254 40 (19.7%) 13 (5.1%)
 >55–75kg 203 40 (19.7%) 22 (10.8%)
 >75kg 16 1 (6.2%) 0 (0.0%)
 Median 51.0 48.3 49.0
 (IQR) (45.0–57.7) (42.3–57.0) (42.5–58.0)
Ethnicity (%)
 Black 295 58 (19.7%) 26 (8.8%)
 Asian 194 47 (24.2%) 20 (10.3%)
 Mixed Race 140 21 (15.0%) 9 (6.4%)
 Other 10 2 (20.0%) 2 (20.0%)
Smoking Hist (%)
 Never 298 63 (21.1%) 27 (9.1%)
 Ex-smoker 155 29 (18.7%) 16 (10.3%)
 Current 186 36 (19.3%) 57 (7.5%)
HIV Status
 Positive 46 20 (43.5%) 11 (23.9%)
 Negative 593 108 (18.2%) 46 (7.8%)
 Median CD4+ (IQR) 365.5 (307.0–456.0) 317.5 (267.5–458.5) 340.0 (267.0–488.0)
Cavities on CXR (%) 456 90 (19.7%) 32 (7.0%)
MGIT Median TTP (IQR) 114 (88–156) 111 (86–163) 118 (95–173)
  1. The baseline characteristics for all patients in the treatment arm are listed along with the baseline characteristics for patients who experienced one or more grade 3 & 4 adverse event related or unrelated. Patients who experienced one or more grade 3 or 4 related adverse event are listed separately. Row percentages are included for each characteristic to show proportions of the total who experienced one or more adverse events